More than two million infants remain completely unvaccinated in the Southeast Asia region: WHO
NEW DELHI: More than two million infants remain completely unvaccinated in the Southeast Asia region, and approximately 6.5 lakh do not receive all the recommended vaccines, the WHO said on April 25.
On the occasion of World Immunisation Week, the World Health Organisation (WHO) said in 59 years, vaccines have saved at least 154 million lives.
'What started in 1974 as the Expanded Programme on Immunization focused on six childhood illnesses and has today evolved to thirteen universally recommended vaccines across the life course. In these 50 years, vaccines have saved at least 154 million lives – a remarkable 6 lives saved each minute, every day, for five decades,' Saima Wazed, Regional Director for WHO South-East Asia Region, said.
'More children now live to see their first birthday than at any other time in human history, and the measles vaccine alone accounts for 60 per cent of those lives saved. Immunisation campaigns have enabled us to eradicate smallpox, eliminate polio in our South-East Asia Region, and bring neonatal and maternal tetanus down to extremely low levels,' she added.
It is clear that vaccines are, undoubtedly, one of humanity's greatest achievements, she stressed.
She said in the region, which includes India, over forty million pregnant women and thirty-seven million newborns are vaccinated annually.
'We are also a global leader in vaccine production, with 46 per cent of the world's supply. These achievements are significant, but we have much more to do. More than two million infants remain completely unvaccinated in our region, and approximately 650,000 do not receive all the recommended vaccines. Covid-19 also saw progress on immunisation stall, resulting in the need for continued catch-up vaccination today. This is evident in the diphtheria and measles outbreaks that have unfortunately started occurring,' she said.
Highlighting that the recent changes in donor budgets in global health has put a severe strain on immunisation programmes everywhere, and have also affected disease surveillance, laboratory networks and outbreak response capacities, she said the confluence of these could lead to tragic outcomes.
'..We urge national governments to boost their EPI investments to ensure the long-term sustainability of immunisation,' she said.
'We are at a crossroads. The hard-won gains in stamping out vaccine-preventable diseases are in jeopardy. We must choose the path of collaborative action, towards hope and health. In walking this path, we must strengthen health systems, address vaccine hesitancy, enhance surveillance, and ensure sustainable financing,' she added.
'The only way forward is together -- governments, health organisations, communities, and individuals -- to protect all the progress we've made, and continue toward a world where no one suffers from a disease that could have been prevented by vaccination,' she said.
On World Immunisation Week, she appealed to them to join in spreading the message that vaccines are safe, vaccines save lives, and immunization for all is essential.
'To do this would be to protect humanity's greatest achievement -- vaccines -- and protect humanity's greatest treasure -- our children,' she added.
World Immunization Week, marked annually in the last week of April, promotes the use of vaccines to protect people of all ages against disease.
The goal of World Immunisation Week is for more people -- and their communities -- to be protected from vaccine-preventable diseases and the theme this year is 'Immunisation for all is humanly possible.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
19 minutes ago
- Hindustan Times
Health Talk: WHO flags RSV deaths in children, calls for new immunisation tools
The World Health Organisation (WHO) recently issued recommendations, including the effective use of immunisation products, to protect infants against Respiratory Syncytial Virus (RSV), which causes acute lower respiratory infections in children and can become life-threatening. RSV, one of the leading causes of under-five mortality globally (which refers to the death of children before their fifth birthday, typically expressed as a rate per 1,000 live births), is responsible for around 1 lakh deaths and over 3.6 million hospitalisations in children under the age of five every year, according to the United Nation health body. About half of these deaths occur in infants younger than six months of age. The vast majority (97%) of RSV deaths in infants occur in low- and middle-income countries, where there is limited access to supportive medical care such as oxygen or hydration. India also has a high disease burden, particularly around the rainy season. A 'position paper' published by WHO outlines recommendations for two immunisation products — a maternal vaccine that can be given to pregnant women in their third trimester to protect their infant, and a long-acting monoclonal antibody that can be administered to infants from birth, just before or during the RSV season. 'RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature, when they are most vulnerable to severe disease,' director of immunization, vaccines, and biologicals at WHO Kate O'Brien said in a statement. 'The WHO-recommended RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalizations, and deaths, ultimately saving many infant lives globally,' he added. A 2021 study — Disease Burden Due to Respiratory Syncytial Virus in Indian Pediatric Population: A Literature Review — said, 'In India, epidemiology of RSV infection is well documented in young children (0-5 years) as compared to children from other age groups. The rates of RSV detection in various studies conducted in younger children (0-5 years) vary from 2.1% to 62.4% in India which is higher as compared to children from other age groups.' RSV usually causes mild symptoms similar to the common cold, including runny nose, cough, and fever. However, it can lead to serious complications — including pneumonia and bronchiolitis — in infants, young children, older adults, and those with compromised immune systems or underlying health conditions. Better management and putting in place preventive measures is largely the key to stopping any disease from turning big. The WHO recommendations will hopefully serve the purpose, and the world will see fewer deaths in children due to RSV.
Hindustan Times
3 hours ago
- Hindustan Times
86.5 lakh deaths in 2022, 15 pc dip over Covid-hit 2021: CRS data
New Delhi, Nearly 86.5 lakh deaths were reported in the country during 2022, a significant decline of more than 15 per cent from Covid-affected 2021 which had recorded over 1.02 crore deaths, according to a new data from the Civil Registration System . The dip of 15.74 lakh from 2021 brought mortality figures broadly back in line with pre-pandemic patterns last seen in 2020, the data for 2022 brought out by the office of the Registrar General of India through CRS report showed. According to the CRS data, 2021 registered a sharp spike with 1.02 crore deaths across the country as compared to 81.1 lakh in 2020, 76.4 lakh in 2019, and 69.5 lakh in 2018, underscoring the impact of COVID-19. "In the case of registered deaths, the number has decreased from 102.2 lakh in 2021 to 86.5 lakh in 2022, i.e. a decrease of 15.4 per cent. Some of the major states namely, Gujarat, Maharashtra, Madhya Pradesh, Andhra Pradesh, Tamil Nadu, Uttar Pradesh, Karnataka, West Bengal, Bihar and Haryana have contributed significantly to the decreased number of registered deaths," the report said. Around 5.26 lakh deaths were reported due to COVID-19 till July 26, 2022, according to a reply given by the government in the Lok Sabha on July 29, 2022. The World Health Organisation had reported over 47 lakh COVID-19 linked deaths in India which was strongly disputed by the government. The Centre had said the WHO estimates suffered from "a number of inconsistencies and erroneous assumptions". "India had registered a strong objection to the process, methodology and outcome of this unscientific modelling approach especially when India had provided authentic data published through Civil Registration System by Registrar General of India to WHO," the government reply had said. The CRS report also showed that over 2.54 crore births were registered in 2022. "The number of registered births has increased from 242.0 lakh in 2021 to 254.4 lakh in 2022, an increase of about 5.1 per cent," the report said. There has been an increase in 2022 in registered births in almost all states and UTs, except Bihar, Haryana, Himachal Pradesh, Sikkim, West Bengal, Ladakh, and Lakshadweep as compared to 2021. Nine major states namely, Uttar Pradesh, Madhya Pradesh, Maharashtra, Jharkhand, Karnataka, Gujarat, Telangana, Chhattisgarh and Assam have contributed significantly to the increase in registered births in 2022 over 2021, the report said. "On the other hand, decrease in registered births in six figures has been observed in two major states namely, West Bengal and Bihar during 2021-2022," it said.
&w=3840&q=100)
First Post
3 hours ago
- First Post
Dr explains: Why booster shots are crucial even with mild Covid-19 symptoms prevailing
India is experiencing a mild surge in COVID-19 cases driven by new Omicron subvariants, with mostly mild symptoms and low hospitalizations. Experts stress the importance of boosters, surveillance and protecting vulnerable groups. Firstpost brings out a doctor's view on symptoms, vaccine effectiveness, and the country's preparedness in tackling the evolving situation. read more According to the Ministry of Health and Family Welfare, India's active Covid-19 cases have reached 5,364 as of Friday, with Kerala remaining the most affected state, reporting over 1,600 active cases. Gujarat, West Bengal, and Delhi follow, with Delhi recording 592 active cases while conducting an average of 1,200 RT-PCR tests daily. The recent surge is primarily driven by newer Omicron subvariants. Firstpost talked to Dr. Diksha Goyal, Consultant – Internal Medicine, Marengo Asia Hospital, Gurugram to shed light on the current Covid-19 scenario, the impact of emerging variants and what people need to know. STORY CONTINUES BELOW THIS AD Reports indicate new variants like LF.7, XFG, JN.1, and NB.1.8.1 are driving the surge. Which of these are currently most prevalent in India? The JN.1 subvariant of Omicron is currently the most widespread in India. Other variants like LF.7, XFG, and NB.1.8.1 are present but less common. All appear to cause mild, self-limiting infections, with no significant rise in severe cases or hospitalisation. Are there any emerging symptoms that differ from previous Covid-19 waves? Yes, while traditional symptoms like fever and cough persist, new symptoms such as hoarseness, sore throat, fatigue, and mild gastrointestinal issues (like nausea or diarrhoea) are increasingly reported. These variants may feel milder but remain highly transmissible. How do current case and hospitalisation numbers compare to earlier waves? The current surge is far less severe than previous waves. Most infections are mild, and the healthcare system is not under strain. Authorities are maintaining readiness, but infrastructure and critical care services are coping well. How deadly are these new variants compared to earlier ones like Delta or previous Omicron strains? Clinically, the newer variants are more contagious but less lethal than the Delta variant. Symptoms are often milder than or similar to previous Omicron subvariants, particularly in vaccinated individuals. However, those at higher risk should remain cautious. The WHO has classified NB.1.8.1 as a 'Variant Under Monitoring.' What does this mean? This label signals genetic changes that could affect how the virus behaves, including its ability to spread or evade immunity. While not currently a major threat, it warrants close observation in case of any future risk. Are specific groups more vulnerable to severe illness with these new variants? Yes. Older adults, immunocompromised individuals, pregnant women, and children remain more susceptible to complications. Their immune systems may be weaker or still developing, so vaccination and preventive measures are essential. With waning immunity, what's your advice on booster doses? Booster shots are crucial, especially for high-risk people. They help sustain protection, reduce the severity of illness, and lower the chance of hospitalisation. Staying up to date with boosters remains a key preventive strategy. How effective are current vaccines against these variants? Do we need new formulations? Existing vaccines still offer strong protection against severe illness, hospitalisation, and death. While they may be less effective at preventing infection, they remain beneficial. Updated formulations targeting newer variants could enhance this protection further. What about people with 'hybrid immunity' from both vaccination and infection? Hybrid immunity offers stronger, more durable protection than either vaccination or infection alone. It significantly reduces the risk of severe illness. However, this immunity may wane over time, so periodic boosters are still recommended. How important is genomic surveillance? Is India prepared? Ongoing surveillance and sequencing are vital for tracking new variants and guiding public health responses. India has ramped up its genomic capabilities, but sustained funding, coordination, and vigilance are needed to remain prepared for future waves. Could Covid-19 become seasonal like the flu? That's a strong possibility. Covid-19 may eventually become endemic with periodic surges, much like influenza. The pattern will depend on factors such as mutations, immunity levels, and public health responses. What key lessons from past waves should guide future responses? The most important lessons are early detection, rapid response, and transparency. Strengthening healthcare infrastructure, ensuring vaccine access, and maintaining public health measures during surges are essential for staying ahead of the virus.
